We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
6 own
2 watching
Current Price
$3.67
$-0.03
(-0.81%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
30.69M
52-Week High
57.21
52-Week Low
3.25
Average Volume
0.26M
Dividend Yield
--
P/E Ratio
20.367
Market Capitalization30.69M
52-Week High57.21
52-Week Low3.25
Average Volume0.26M
Dividend Yield--
P/E Ratio20.367
What does the Stockal+Disclaimer.pdf do?
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People s Republic of China.
Read More
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
2 months ago
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 PR Newswire GAITHERSBURG, MD. and SHANGHAI, China, Oct. 5, 2022 GAITHERSBURG...
PR Newswire
2 months ago
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic...
Business Wire
3 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab (I-Mab or the Company) (NASDAQ: IMAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading...
PR Newswire
3 months ago
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 PR Newswire GAITHERSBURG, Md. and SHANGHAI...
PR Newswire
4 months ago
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China PR Newswire...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$3.67
$-0.03
(-0.81%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00